Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Equity Ratio (2020 - 2022)

Atea Pharmaceuticals has reported Equity Ratio over the past 3 years, most recently at 0.97 for Q3 2022.

  • Quarterly results put Equity Ratio at 0.97 for Q3 2022, up 40.13% from a year ago — trailing twelve months through Sep 2022 was 0.97 (up 40.13% YoY), and the annual figure for FY2021 was 0.92, up 44.84%.
  • Equity Ratio for Q3 2022 was 0.97 at Atea Pharmaceuticals, up from 0.95 in the prior quarter.
  • Over the last five years, Equity Ratio for AVIR hit a ceiling of 0.97 in Q3 2022 and a floor of 0.69 in Q3 2020.
  • Median Equity Ratio over the past 3 years was 0.7 (2021), compared with a mean of 0.64.
  • Biggest five-year swings in Equity Ratio: skyrocketed 199.2% in 2021 and later soared 35.93% in 2022.
  • Atea Pharmaceuticals' Equity Ratio stood at 0.63 in 2020, then surged by 44.84% to 0.92 in 2021, then rose by 5.14% to 0.97 in 2022.
  • The last three reported values for Equity Ratio were 0.97 (Q3 2022), 0.95 (Q2 2022), and 0.95 (Q1 2022) per Business Quant data.